Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

Study acronym: REPIFIR
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 15 → 19 locations
    • Primary and study completion dates: Dec 2031 to Dec 27, 2031
    • Eligibility criteria expanded, about 34 words
    • Secondary endpoints: details revised at 2 of 13 entries
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy until cycle 12 or change to combination therapy (epcoritamab + tafasitamab + lenalidomide) until cycle 15. Patients will be followed up to 5 years.
Trial Details
NCT Number NCT07126236
Lead Sponsor Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Collaborators: AbbVie, Incyte Corporation, Evidenze CRO
Conditions
(from sponsor)		 Large B Cell Lymphoma
Related terms Lymphoma, Lymphoma, Large B-Cell, Diffuse, Recurrence
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov